5-MeO-DMT's Anxiolytic Effects in Mice 5-MeO-DMT altered gene expression in brain regions related to neuroplasticity and exhibited both anxiolytic and anxiogenic effects in mice. #ICYMI doi.org/10.1038/s41380…

Blood-Brain Barrier Modulation and #Neuroplasticity Neuronal activity increased #BBB permeability in the somatosensory cortex, which was linked to long-term synaptic plasticity; study of rats combined with human MRI imaging. #ICYMI #Research doi.org/10.7554/eLife.…

Psylo's Neuroscience Newsletter, August 🧠 - mailchi.mp/psylo/psylo-sc…

Psylo's Neuroscience Newsletter, August 🧠 - mailchi.mp/psylo/psylo-sc…

Excited to see Dr. William Jorgensen, Psylo's Director of Medicinal Chemistry, presenting at the ASCEPT meeting this week! Will is a highly accomplished EMCR with a wealth of experience across academia, industry, and startups. Don't miss it! #ASCEPT2024

Or if you're attending the 7th Neuropsychiatric Drug Development Summit, don't miss our panel on navigating the commercial challenges of reimbursement & market access for psychiatric therapeutics. 🗓️ 9/26, 4 PM 🔗 neuropsychiatric-drug-development.com/seminar/panel-…

Psylo's Neuroscience Newsletter, September 🧠 - New findings in anxiety, depression and addiction, brain connectivity, predicting efficacy, sex differences, neuroplasticity, new tools, and exploring molecular targets of psychedelics beyond 5-HT2A. psylo.bio/news/psylo-new…

The binding modes of serotonin 2A agonists (blue) vs. antagonists (red) are clear when superimposed. Antagonists occupy space that agonists do not.

Psilocybin as an alternative treatment for depression: “The more flexible a patient’s brain was 3 weeks after 1 trip, the better their outcome on depression at 6 months,” Prof Nutt said, suggesting cognitive flexibility as a possible therapeutic mechanism cnn.com/2024/10/22/hea…

Innovative trial will use psilocybin-assisted therapy to target relapse in opioid addiction Imperial College London imperial.ac.uk/news/257294/in…

Non-hallucinogenic psychedelics are challenging the idea that 'tripping' is essential for therapeutic benefits. As they are investigated for various mental health conditions like depression and addiction, they could redefine mental health treatments. theatlantic.com/health/archive…

2 University of Sydney researchers secure $6M from Cooperative Research Australia (CRA)! ⭐️Cameron Kepert will develop advanced materials for efficient hydrogen storage. ⭐️Nick Everett will address the challenges of developing effective mental health treatments. Read more: tinyurl.com/k67nzae5

Psylo is joining forces with Tessara Therapeutics & University of Sydney to advance neuroplastogen development for treating addiction! 🚀🧠 We aim to reshape and ‘rewire’ how we tackle substance use disorders. Learn more: prnewswire.com/news-releases/…

Congrats to Dr Nick Everett @Psylo_Bio, Tessera Therapeutics awarded $3 million in a CRC-P grant to develop novel neuroplastogens for the treatment of substance use disorders! #LeadershipForGood Read ➡️ bit.ly/CRCPGrant3MNic… Sydney Science University of Sydney

💜 WE VISITED @Psylo_Bio 💜 Last week, co-founder of @Psylo_Bio, Josh Ismin invited the community into the @Psylo_Bio labs! PLUS they have been awarded a $3 million CRC-P grant to develop novel neuroplastogens for the treatment of substance use disorders! Ummm WOW! 🤩

Classic psychedelics like psilocybin and LSD show promise for mental health treatment, but intense side effects like vivid hallucinations remain a barrier. @Psylo_Bio, in collaboration with Associate Professor Luke Hunter at UNSW Science, is developing psilocybin-like